Inhibitor Therapeutics Inc. (INTI)

Overview

Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on the creation and commercialization of therapies for patients dealing with certain types of cancer and non-cancerous proliferation disorders in the United States. Originally known as HedgePath Pharmaceuticals, Inc., the company underwent a name change to Inhibitor Therapeutics, Inc. in August 2019. Since its establishment in 1992, the company has rooted its operations in Tampa, Florida, dedicating its efforts to the development of innovative treatments for devastating diseases like prostate and lung cancer.

Products and Services

• SUBA-Itraconazole for Prostate and Lung Cancer:

This is an oral formulation of the drug itraconazole, which has been tailored by Inhibitor Therapeutics for the treatment of prostate and lung cancer. It represents a significant part of the company's pipeline and showcases their commitment to advancing therapeutic options for cancer patients.

• Phase 2b Study of SUBA-Itraconazole for Basal Cell Carcinoma Nevus Syndrome:

The company has achieved a positive outcome in the Phase 2b study of SUBA-Itraconazole, targeting the treatment of basal cell carcinoma nevus syndrome. This demonstrates Inhibitor Therapeutics’ capability in conducting successful clinical research and development endeavors aimed at addressing specific cancerous conditions.